Clinical Edge Journal Scan

Does metabolic syndrome influence outcomes in triple-negative breast cancer?


 

Key clinical point: Metabolic syndrome (MS) is associated with poorer disease-free survival (DFS), but not with overall survival (OS) in patients with triple-negative breast cancer (TNBC). Hypertension was the only MS component associated with poor DFS and OS.

Major finding: MS was significantly associated with poor DFS (adjusted HR [aHR], 2.24; P = .030), but not OS (aHR, 1.92; P = .103). Hypertension was significantly associated with worse DFS (aHR, 3.63; P = .006) and OS (aHR, 3.45; P = .035).

Study details: Retrospective study of 177 patients with TNBC with (n=48) or without (n=129) MS who were followed-up for at least 5 years.

Disclosures: The study was supported by the Sharpe Strumia Foundation. The authors declared no conflicts of interest.

Source: Kennard K et al. Breast Cancer Res Treat. 2021 Jan 3. doi: 10.1007/s10549-020-06034-1 .

Recommended Reading

Model predicts acute kidney injury in cancer patients a month in advance
MDedge Hematology and Oncology
COVID-19 vaccination in cancer patients: NCCN outlines priorities
MDedge Hematology and Oncology
Obesity ‘clearly’ not tied to worse survival in metastatic breast cancer
MDedge Hematology and Oncology
Findings could change breast cancer risk management
MDedge Hematology and Oncology
Aspirin linked to reduced bladder, breast cancer mortality
MDedge Hematology and Oncology
Study flags cardiovascular disease in men with breast cancer
MDedge Hematology and Oncology
Clinical Edge Commentary: Breast Cancer February 2021
MDedge Hematology and Oncology
Partial breast irradiation vs. whole breast irradiation for early breast cancer
MDedge Hematology and Oncology
One-third of HER2+ and triple-negative metastatic breast cancer patients develop brain metastases
MDedge Hematology and Oncology
Palbociclib+ET fails to prolong PFS in AI-resistant metastatic breast cancer
MDedge Hematology and Oncology